comprehensive -WSS

comprehensive

author：focus 2025-09-27 23:53:40 - browse：4721

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Galapagos to make CAR

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Galapagos to make CAR

Patient advocates sound warning on FDA proposal on salt intake

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Hottest summer in 2,000 years puts focus on extreme heat, health

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical records are filled with copy

The pain doctors face in trying to build their families

Medicare proposal to cover medical devices draws a mixed reaction

Hilary may become 1st tropical storm to make landfall in California in 84 years

Guidelines to prevent youth baseball injuries need more muscle

New definition of a human embryo proposed amid rapid advances

Hepatitis C has a cure — but many Americans still lack access to it

Living with Hashimoto's and celiac disease, and med school, too

Bright Health sells Medicare Advantage business to Molina

As Maui death toll rises, number of missing remains unclear

entertainment

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Free medical tuition alone isn't enough to close gaps in primary care

FDA approves first treatment for ultra

Ripples from Flovent's discontinuation is killing children with asthma

Trump cancels press conference intended to dispute Georgia election interference charges

Evacuations in place as 3 wildfires burn in eastern Washington state

knowledge

leisure time

leisure time

leisure time